A nanomicelle with miR-34a and doxorubicin reverses the drug resistance of cisplatin in esophageal carcinoma cells by inhibiting SIRT1 signal pathway

Department of Radiation Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China; Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China; Department of Radiology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China; Key Laboratory of Head & Neck Cancer Translational Research of Zhejiang Province, Hangzhou, China; Department of Radiation Oncology, Quzhou Kecheng Hospital, Quzhou, China Contributions: (I) Conception and design: Z Ye; (II) Administrative support: Y Wang, Z Zhen; (III) Provision of study materials or patients: Z Wang, T Xie; (IV) Collection and assembly of data: F Yan, L Wang; (V) Data analysis and interpretation: J Fang, J Hua; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. These authors contributed equally to this work. Correspondence to: Zhimin Ye; Zhenfu Fu. Department of Radiation Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Banshan East Road, Gongshu District, Hangzhou, China; Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China; Key Laboratory of Head & Neck Cancer Translational Research of Zhejiang Province, Banshan East Road, Gongshu District, Hangzhou, China. Email: yezm@zjcc.org.cn; fuzf1000@163.com.